Infections in the Hematopoietic Cell Transplantation Setting: Improving Outcomes Through Interdisciplinary Care

Are you a physician or other non-pharmacist healthcare professional? Please go to the site of our collaborator, Terranova Medica, to participate in this activity and receive ACCME or IPCE credits. Click here to access.


Jointly provided by Postgraduate Institute for Medicine(PIM); ProCE, Inc.; Society of Infectious Diseases Pharmacists Education Center (SIDPEC); and Terranova Medica, LLC.  

Activity Description

Despite advances in management, infections with bacterial, viral, and fungal pathogens remain among the most common causes of mortality in hematopoietic stem cell transplantation (HCT). Performance gaps exist in the management of recurrent Clostridioides infections, prevention of cytomegalovirus infections, recognition of CMV infections as a risk factor for fungal infections, and management of hospital-acquired and ventilator-acquired bacterial pneumonia. This activity discusses evidence-based approaches to management of these infections in the HCT setting, with a particular emphasis on interdisciplinary management.

Learning Objectives

This activity is directed to infectious disease physicians, critical care physicians, hospitalists, surgeons, pathologists, hematologists/oncologists, pharmacists, and other healthcare providers responsible for the prevention and management of infections in the HCT setting. At the completion of this activity, the participant will be better able to:

  • Identify risk factors for recurrent Clostridioides difficile infection (CDI) in patients undergoing hematopoietic cell transplantation (HCT).
  • Provide patient-tailored therapy for CDI in patients undergoing HCT.
  • Select appropriate therapy to prevent and manage cytomegalovirus (CMV) infection in patients undergoing HCT.
  • Examine the interrelationship between CMV infection and fungal infection in patients undergoing HCT.
  • Select appropriate therapy for hospital-acquired and ventilator-associated pneumonia (HABP/VABP) in patients undergoing HCT.
  • Describe interdisciplinary team-based approaches to manage infections in the HCT setting.


Carolyn Alonso, MD, FIDSA
Assistant Professor of Medicine, Harvard Medical School
Division of Infectious Diseases, Beth Israel Deaconess Medical Center
Director, Transplant and immunocompromised Host Infectious Diseases Service
Boston, Massachusetts

Vasilios Athans, PharmD, BCPS, BCIDP
Infectious Diseases Clinical Pharmacy Specialist
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Dayna McManus, PharmD, BCPS, AQ-ID
Senior Clinical Pharmacy Specialist—Infectious Diseases
Residency Program Director
Yale New Haven Hospital
New Haven, Connecticut

Jennifer L. Saullo, MD, PharmD
Assistant Professor of Medicine
Department of Medicine
Duke University School of Medicine
Durham, North Carolina

Frank Tverdek, PharmD, BCPS, AQ-ID, CMQ
Clinical Pharmacy Manager, Clinical Pharmacy Programs
Clinical Pharmacy Specialist, Infectious Diseases
MD Anderson Cancer Center
Houston, Texas

Eduardo Yepez Guevara, MD
Assistant Professor
Department of Infectious Diseases
Infection Control and Employee Health
Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

CE Accreditation

Release Date: 2-28-2020
Expiration Date: 2-28-2021


This activity is jointly provided by ProCE, Inc., PIM, the Society of Infectious Diseases Pharmacists, and Terranova Medica, LLC. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-017-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. The following indicates the disclosure declaration information and the nature of those commercial relationships:


Carolyn Alonso, MD, FIDSA
FINANCIAL SUPPORT: Alnylam Pharmaceuticals (salary [spouse]); Moderna Therapeutics (stock sale [spouse])

Vasilios Athans, PharmD, BCPS, BCIDP
No conflicts to disclose.

Dayna McManus, PharmD, BCPS, AQ-ID
No conflicts to disclose.

Jennifer L. Saullo, MD, PharmD
No conflicts to disclose.

Frank Tverdek, PharmD, BCPS, AQ-ID, CMQ
No conflicts to disclose.

Eduardo Yepez Guevara, MD
No conflicts to disclose.

The PIM, ProCE, and Terranova Medica, LLC planners and managers have nothing to disclose. Melissa Johnson, PharmD, MHS, AAHIVP, of the SIDPEC, discloses the following: advisory board for Paratek; Astellas; Shionogi & Company, Ltd.; and Cidara Therapeutics; research support from Merck & Co., Inc. and Shionogi & Company, Ltd.; and royalties from UpToDate.


This activity is supported by an educational grant from Merck & Co., Inc.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Credit Information

Activity Number Credit Amount Accreditation Period
0221-9999-20-017-H01-P 1.5 Contact Hours February 28, 2020 - February 28, 2023